15 November 2018  
EMA/CHMP/790642/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
MabThera 
rituximab 
On 15 November 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
MabThera. The marketing authorisation holder for this medicinal product is Roche Registration GmbH. 
The CHMP adopted an extension to an existing indication as follows:2 
“Granulomatosis with polyangiitis and microscopic polyangiitis  
MabThera, in combination with glucocorticoids, is indicated for the induction of remission in 
treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) 
and microscopic polyangiitis (MPA).” 
For information, the full indications for MabThera will be as follows: 
“MabThera is indicated in adults for the following indications: 
Non-Hodgkin’s lymphoma (NHL) 
MabThera is indicated for the treatment of previously untreated patients with stage III-IV follicular 
lymphoma in combination with chemotherapy.  
MabThera maintenance therapy is indicated for the treatment of follicular lymphoma patients 
responding to induction therapy.  
MabThera monotherapy is indicated for treatment of patients with stage III-IV follicular lymphoma 
who are chemoresistant or are in their second or subsequent relapse after chemotherapy.  
MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell 
non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, 
prednisolone) chemotherapy.  
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
Chronic lymphocytic leukaemia (CLL) 
MabThera in combination with chemotherapy is indicated for the treatment of patients with 
previously untreated and relapsed/refractory CLL. Only limited data are available on efficacy and 
safety for patients previously treated with monoclonal antibodies including MabThera or patients 
refractory to previous MabThera plus chemotherapy. 
See section 5.1 for further information. 
Rheumatoid arthritis 
MabThera in combination with methotrexate is indicated for the treatment of adult patients with 
severe active rheumatoid arthritis who have had an inadequate response or intolerance to other 
disease modifying anti rheumatic drugs (DMARD) including one or more tumour necrosis factor 
(TNF) inhibitor therapies. 
MabThera has been shown to reduce the rate of progression of joint damage as measured by X ray 
and to improve physical function, when given in combination with methotrexate. 
Granulomatosis with polyangiitis and microscopic polyangiitis  
MabThera, in combination with glucocorticoids, is indicated for the treatment of adult patients with 
severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis 
(MPA).” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
MabThera  
EMA/CHMP/790642/2018 
Page 2/2 
 
  
  
 
